HX575 recombinant human erythropoietin alfa

Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.